AzurRx BioPharma, Inc. (Form: 8-K, Received: 01/05/2018 17:06:29)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 31, 2017

AZURRX BIOPHARMA, INC.

(Exact name of Registrant as specified in its Charter)

Delaware	001-37853	46-4993860
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, New York		11226
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (646) 699-7855

(Name, address, including zip code, and telephone number, including area code, of agent for service of process)

NOT APPLICABLE

(Former Name or Former Address, if Changes Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 1.01

Entry into a Material Definitive Agreement.

As previously reported, on June 5, 2017, AzurRx BioPharma, Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ 2017 Agreements ”) and a registration rights agreement with certain accredited investors pursuant to which the Company issued an aggregate of 1,428,572 units for $3.50 per unit, with each unit consisting of one share of common stock, $0.0001 par value (“ Common Stock ”), one Series A Warrant to purchase 0.25 shares of Common Stock at $4.00 per share exercisable immediately through December 31, 2017, and one Series A-1 Warrant to purchase 0.75 shares of Common Stock at $5.50 per share exercisable beginning six months from the date of issuance through June 5, 2022.

Also as previously reported, commencing on October 14, 2014, the Company issued warrants to purchase shares of Common Stock in conjunction with the issuance of original issuance discount notes (“ OID Note ”). These warrants are exercisable for five years beginning six months after the issue date for $5.58 per share, and provide to the holders thereof certain registration rights (the “ OID Warrants ”). Subsequently, on October 14, 2016, the Company completed an initial public offering (“ IPO ”) of 960,000 shares of Common Stock at a price of $5.50 per share and concurrent with the IPO, the Company issued certain securities, including 717,540 warrants with a five-year life to holders of the OID Notes in exchange for their agreement not to sell their shares for six months following the IPO with an exercise price equal to the IPO price (the “ Lock-Up Warrants ”).

Beginning on December 31, 2017, the Company and certain holders (the “ Holders ”) of the Series A Warrants, Series A-1 Warrants, OID Warrants and Lock-Up Warrants (collectively, the “ Warrants ”) entered into warrant repricing letter agreements in the form attached hereto as Exhibit 10.1 (the “ Exercise Agreements ”) with Holders of an aggregate total of 264,402 Warrants, and warrant repricing letters in the form attached hereto as Exhibit 10.2 (the “ Partial Exercise Agreements ”) with Holders of an aggregate total of 217,206 Warrants, pursuant to which the Company agreed to reduce the exercise price of an aggregate total of 108,603 Warrants held by such Holders (the “ Reprice Warrants ”) to $2.50 per share (the “ Reduced Exercise Price ”) in consideration for the exercise in full of the Reprice Warrants, and agreed to amend an aggregate total of 108,604 remaining, unexercised Warrants held by certain Holders (the “ Remaining Warrants ”) to reduce the exercise of the Remaining Warrants to $3.25 per share. If the exercise of the Reprice Warrants would cause the Holder to exceed the 4.99% or 9.99% beneficial ownership limitations (“ Beneficial Ownership Limitation ”) (as defined in the Warrants), then the Company will only issue such number of shares to the Holder as instructed by the Holder and as would not cause such Holder to exceed the maximum number of shares permitted under the Beneficial Ownership Limitation, with the balance of shares to be held in abeyance until the balance may be issued in compliance with such limitations.

The Company expects to receive aggregate gross proceeds of approximately $932,511 from the exercise of the Warrants by the Holders.

The description of terms and conditions of the Exercise Agreements and the Partial Exercise Agreements set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Exercise Agreement and Partial Exercise Agreement attached hereto as Exhibits 10.1 and 10.2.

Item 3.03

Material Modifications to Rights of Security Holders.

See Item 1.01 above.

Item 9.01

Financial Statements and Exhibits.

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	AzurRx BioPharma, Inc .

Date: January 5, 2018	By:	/s/ Johan M. Spoor
		Name: Johan M. Spoor
		Title: Chief Executive Officer

Exhibit Index

Exhibit Number		Description

10.1		Form of Exercise Letter
10.2		Form of Partial Exercise Letter

Exhibit 10.1

December ___, 2017

[Holders’ names and addresses]

Re:

Reprice Offer of Common Stock Purchase Warrants

To Whom It May Concern:

AzurRx BioPharma, Inc. (the “ Company ”) is pleased to offer to you the opportunity to reprice the exercise of all common stock purchase warrants currently held by you (the “ Holder ”) and set forth on the signature page hereto (the “ Reprice Warrants ”), which Reprice Warrants may include Common Stock purchase warrants first issued on or about June 5, 2017 that have an exercise price of $4.00 per share and are set to expire on December 31, 2017 (the “ $4.00 Warrants ”). The Reprice Warrants and the shares of common stock, par value $0.0001 per share (“ Common Stock ”), underlying the Reprice Warrants (“ Warrant Shares ”) have been registered pursuant to registration statement on Form S-1 (File No. 333-219385) (the “ Registration Statement ”). The Registration Statement is currently effective and, upon exercise of the Reprice Warrants, will be effective for the issuance of the Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Warrant Agreement, dated as of ________, 20__, between the Company and the Holder (“ Warrant Agreement ”), pursuant to which the Company issued warrants (the “ Warrants ”), including certain of the Reprice Warrants.

In consideration for the exercise of all Reprice Warrants (each, a “ Warrant Exercise ”), the Company hereby offers you a reduced exercise price of the Reprice Warrants to $2.50 (the “ Reduced Price ”) from the date hereof until January 7, 2018 (such period, the “ Exercise Period ”); provided , however , the Exercise Period will not extend the expiration date of the $4.00 Warrants past December 31, 2017. The Holder may exercise the Reprice Warrants at any time and from time to time during the Exercise Period, or, in the case of the $4.00 Warrants, on or before December 31, 2017, but the Holder is under no obligation to exercise any of the Reprice Warrants. By executing this letter agreement, the Holders acknowledges that the Company is only offering the Reduced Price to you in consideration for exercising all Common Stock purchase warrants currently held the Holder.

In connection with the transactions described herein, the Company agrees to the representations, warranties and covenants set forth on Annex A attached hereto.

If this Offer is accepted and this letter agreement is executed on or before 8:00 a.m. (New York City time) on January 7, 2018 and the aggregate Exercise Price for all Reprice Warrants is received by the Company, then the Company shall file a Current Report on Form 8-K with the Securities and Exchange Commission within four (4) trading days of receiving such funds disclosing all material terms of the transactions contemplated hereunder, including a form of this agreement as an exhibit thereto (“ 8-K Filing ”). The Company shall file a prospectus supplement to the Registration Statement with the Securities and Exchange Commission disclosing the Reduced Price of the Reprice Warrants within one (1) trading day following the 8-K Filing. From and after the issuance of the 8-K Filing, the Company represents to the Holder that it shall not be in possession of any material, nonpublic information received from the Company, any of its Subsidiaries or any of their respective officers, directors, employees or agents that is not disclosed in the 8-K Filing. The Company represents, warrants and covenants that, upon each Warrant Exercise, all of the Warrant Shares shall be delivered electronically through the Depository Trust Company within ten (10) business day of the date the Company receives the aggregate Exercise Price (or, with respect to shares of Common Stock that would otherwise be in excess of the Beneficial Ownership Limitation, within ten (10) business day of the date the Company is notified by Holder that its ownership is less than the Beneficial Ownership Limitation). Except as set forth herein, the terms of the Reprice Warrants, including but not limited to the obligations to deliver the Warrant Shares, shall remain in effect. In the event any conflicts between this letter agreement and the terms and conditions set forth in any Reprice Warrant arise, the terms and conditions set forth in this letter agreement shall control.

The Company acknowledges and agrees that the obligations of the Holder under this letter agreement are several and not joint with the obligations of any other holder of Common Stock purchase Warrants of the Company (each, an “ Other Holder ”) under any other agreement related to the exercise of such Warrants (“ Other Warrant Exercise Agreement ”), and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holder pursuant hereto, shall be deemed to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for such purpose.

***************

760 Parkside Avenue Downstate Biotechnology Incubator Suite 304 Brooklyn, NY 11226

646-699-7855 info@azurrx.com

-1-

To accept this offer, Holder must counter execute this letter agreement and return the fully executed agreement to the Company at e-mail: ________, attention: _______, on or before 8:00 am (New York City time) on _________, 20__.

Please do not hesitate to call me if you have any questions.

Sincerely yours,

AZURRX BIOPHARMA, INC.

By: ______________________

Name: Johan M. (Thijs) Spoor

Title: President and Chief Executive Officer

Accepted and Agreed to:

Name of Holder: ________________________________________________________

Signature of Authorized Signatory of Holder : _________________________________

Name of Authorized Signatory: _______________________________________________

Title of Authorized Signatory: ________________________________________________

Aggregate Exercise Price to be delivered to the Company: __________________________

DTC Instructions:

Reprice Warrants :

Warrant No.	Issuance Date	Expiration Date	No. of Warrant Shares	Original Exercise Price

-2-

Annex A

Representations, Warranties and Covenants of the Company . The Company hereby makes the following representations and warranties to the Holder:

(a) Registration Statement . The Warrant Shares are registered for issuance on a Registration Statement on Form S-1 (File No. 333-219385) (the “ Registration Statement ”) and the Company knows of no reasons why such registration statement shall not remain available for the issuance and resale of such Warrant Shares for the foreseeable future. The Company shall use commercially reasonable efforts to keep the Registration Statement effective and available for use by the Holder until all Warrant Shares underlying the Reprice Warrants are sold by the Holder.

(b) Authorization; Enforcement . The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally; (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(c) No Conflicts . The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected.

(d) Nasdaq Corporate Governance . The transactions contemplated under this letter agreement, comply with all rules of the Nasdaq Stock Market.

760 Parkside Avenue Downstate Biotechnology Incubator Suite 304 Brooklyn, NY 11226

646-699-7855 info@azurrx.com

-3-

Exhibit 10.2

December ___, 2017

[Holders’ names and addresses]

Re:

Reprice Offer of Common Stock Purchase Warrants

To Whom It May Concern:

AzurRx BioPharma, Inc. (the “ Company ”) is pleased to offer to you the opportunity to reprice the exercise of the common stock purchase warrants set forth on the signature page hereto (the “ Reprice Warrants ”), which represents at least one-half of the common stock purchase warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), currently held by you (the “ Holder ”), which Reprice Warrants may include Common Stock purchase warrants first issued on or about June 5, 2017 that have an exercise price of $4.00 per share and are set to expire on December 31, 2017 (the “ $4.00 Warrants ”). The Reprice Warrants, the Remaining Warrants (defined below) and the shares of common stock, par value $0.0001 per share (“ Common Stock ”), underlying the Reprice Warrants and the Remaining Warrants (“ Warrant Shares ”) have been registered pursuant to registration statement on Form S-1 (File No. 333-219385) (the “ Registration Statement ”). The Registration Statement is currently effective and, upon exercise of the Reprice Warrants and the Remaining Warrants, will be effective for the issuance of the Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Warrant Agreement, dated as of ________, 20__, between the Company and the Holder (“ Warrant Agreement ”), pursuant to which the Company issued warrants (the “ Warrants ”), including the Reprice Warrants and the Remaining Warrants.

In consideration for the exercise of the Reprice Warrants (each, a “ Warrant Exercise ”), the Company hereby offers you a reduced exercise price of the Reprice Warrants to $2.50 (the “ Reduced Price ”) from the date hereof until January 7, 2018 (such period, the “ Exercise Period ”); provided , however , the Exercise Period will not extend the expiration date of the $4.00 Warrants past December 31, 2017. The Holder may exercise the Reprice Warrants at any time and from time to time during the Exercise Period, or, in the case of the $4.00 Warrants, on or before December 31, 2017, but the Holder is under no obligation to exercise any of the Reprice Warrants. By executing this letter agreement, the Holders acknowledges that the Company is only offering the Reduced Exercise Price in consideration for exercising at least one-half of the Common Stock purchase warrants currently held by the Holder.

In addition, the Company hereby offers to amend each of your Common Stock purchase warrants that are not Reprice Warrants (the “ Remaining Warrants ”), to reduce the applicable exercise price thereof to $3.25 per share. A list of the Remaining Warrants is set forth on the signature page hereto.

In connection with the transactions described herein, the Company agrees to the representations, warranties and covenants set forth on Annex A attached hereto.

If this Offer is accepted and this letter agreement is executed on or before 8:00 a.m. (New York City time) on January 7, 2018 and the aggregate Exercise Price for all Reprice Warrants is received by the Company, then the Company shall file a Current Report on Form 8-K with the Securities and Exchange Commission within four (4) trading days of receiving such funds disclosing all material terms of the transactions contemplated hereunder, including a form of this agreement as an exhibit thereto (“ 8-K Filing ”). The Company shall file a prospectus supplement to the Registration Statement with the Securities and Exchange Commission disclosing the Reduced Price of the Reprice Warrants and the amendment of the Remaining Warrants within one (1) trading day following the 8-K Filing. From and after the issuance of the 8-K Filing, the Company represents to the Holder that it shall not be in possession of any material, nonpublic information received from the Company, any of its Subsidiaries or any of their respective officers, directors, employees or agents that is not disclosed in the 8-K Filing. The Company represents, warrants and covenants that, upon each Warrant Exercise, all of the Warrant Shares shall be delivered electronically through the Depository Trust Company within ten (10) business day of the date the Company receives the aggregate Exercise Price (or, with respect to shares of Common Stock that would otherwise be in excess of the Beneficial Ownership Limitation, within ten (10) business day of the date the Company is notified by Holder that its ownership is less than the Beneficial Ownership Limitation). Except as set forth herein, the terms of the Reprice Warrants and the Remaining Warrants, including but not limited to the obligations to deliver the Warrant Shares, shall remain in effect. In the event any conflicts between this letter agreement and the terms and conditions set forth in any Reprice Warrant or Remaining Warrant arise, the terms and conditions set forth in this letter agreement shall control.

***************

760 Parkside Avenue Downstate Biotechnology Incubator Suite 304 Brooklyn, NY 11226

646-699-7855 info@azurrx.com

-1-

Please do not hesitate to call me if you have any questions.

Sincerely yours,

AZURRX BIOPHARMA, INC.

By: ______________________

Name: Johan M. (Thijs) Spoor

Title: President and Chief Executive Officer

Accepted and Agreed to:

Name of Holder: ________________________________________________________

Signature of Authorized Signatory of Holder : _________________________________

Name of Authorized Signatory: _______________________________________________

Title of Authorized Signatory: ________________________________________________

Aggregate Exercise Price to be delivered to the Company: __________________________

DTC Instructions:

Reprice Warrants :

Warrant No.	Issuance Date	Expiration Date	No. of Warrant Shares	Original Exercise Price

Remaining Warrants :

Warrant No.	Issuance Date	Expiration Date	No. of Warrant Shares	Original Exercise Price

-2-

Annex A

Representations, Warranties and Covenants of the Company . The Company hereby makes the following representations and warranties to the Holder:

(d) Nasdaq Corporate Governance . The transactions contemplated under this letter agreement, comply with all rules of the Nasdaq Stock Market.

760 Parkside Avenue Downstate Biotechnology Incubator Suite 304 Brooklyn, NY 11226

646-699-7855 info@azurrx.com

-3-